Long-acting injectable medication Lenacapavir planned for HIV prevention launch in Georgia

Georgia is preparing to roll out the innovative long-acting injectable antiretroviral medication Lenacapavir for HIV prevention, positioning the country as a regional pioneer in adopting advanced preventative treatments, healthcare officials confirmed on Wednesday.

The announcement follows a World Health Organisation (WHO) regional workshop held in Uzbekistan on 29–30 September, focused on bolstering collective measures against HIV infection and tuberculosis.

Professor Akaki Abutidze, Deputy Scientific Director of the Tengiz Tsertsvadze Centre for Infectious Pathology and AIDS, represented Georgia at the summit. He presented the nation’s progress and clinical achievements in HIV prevention and therapeutic care to the international medical community.

A primary focus of the summit centred on the implementation of Lenacapavir, a long-acting injectable regimen designed for HIV pre-exposure prophylaxis.

“Georgia will be the first country in the region to introduce this innovative approach,'” the Centre for Infectious Pathology and AIDS said in a statement. “‘This development reconfirmed that Georgia’s HIV/AIDS medical service remains a regional leader in adopting modern preventive strategies, integrating medical innovations, and exchanging international expertise.”